Amgen/Wyeth Enbrel
Executive Summary
Wyeth/Amgen's Enbrel clears FDA Aug. 21 for supplemental indication of "inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis." Enbrel (etanercept) was approved for "reducing the signs and symptoms" of psoriatic arthritis in 2002 (1"The Pink Sheet" Jan. 21, 2002, p. 25)...